natgillin/translations-raw huggingface dataset:
Vancomycin Hikma VANCOMYCIN 1000MG VIAL 
Vancomycin Hikma VANCOMYCIN 1000MG BOČICA
Vancomycine Hikma VANCOMYCIN 500MG VIAL 
Vancomycine Hikma VANCOMYCIN 500MG BOČICA
1000MG vial 
1000MG BOČICA
513MG Vial 
513MG BOČICA
VANCOMYCIN HYDROCHLORIDE 512MG VIAL 
VANCOMYCIN HYDROCHLORIDE 512MG BOČICA
Cnp Pharma Gmbh Vancomycin "cnp" VANCOMYCIN 500MG VIAL 
Cnp Pharma Gmbh Vancomycin "cnp" VANCOMYCIN 500MG BOČICA
VANCOMYCIN HYDROCHLORIDE 512.57MG VIAL 
VANCOMYCIN HYDROCHLORIDE 512.57MG BOČICA
500MG VIAL 
500MG BOČICA
Vancomicina Hikma VANCOMYCIN Hydrochloride 500 mg vial 
Vancomicina Hikma VANCOMYCIN Hydrochloride 500 mg BOČICA
Vancomicina Hikma VANCOMYCIN HYDROCHLORIDE 500 mg vial 
Vancomicina Hikma VANCOMYCIN HYDROCHLORIDE 500 mg BOČICA
Vancomycine Hikma VANCOMYCIN 1000MG VIAL 
Vancomycine Hikma VANCOMYCIN 1000MG BOČICA
Vancomycin Nrim VANCOMYCIN 1000MG VIAL 
Vancomycin Nrim VANCOMYCIN 1000MG BOČICA
Vancomycin Nrim VANCOMYCIN 500MG VIAL 
Vancomycin Nrim VANCOMYCIN 500MG BOČICA
Trading 
Laboratórios
Vancomycine Mylan VANCOMYCIN 500MG VIAL 
Vancomycine Mylan VANCOMYCIN 500MG BOČICA
VANCOMYCIN Hydrochloride1000MG VIAL 
VANCOMYCIN Hydrochloride1000MG BOČICA
Vancomycin Mylan VANCOMYCIN 500MG VIAL 
Vancomycin Mylan VANCOMYCIN 500MG BOČICA
Cnp Pharma Gmbh Vankomicin Cnp VANCOMYCIN 1000MG VIAL 
Cnp Pharma Gmbh Vankomicin Cnp VANCOMYCIN 1000MG BOČICA
Vankomicin Pfizer VANCOMYCIN 1000MG VIAL 
Vankomicin Pfizer VANCOMYCIN 1000MG BOČICA
Cnp Pharma Gmbh Vancomycine Cnp VANCOMYCIN 500MG VIAL 
Cnp Pharma Gmbh Vancomycine Cnp VANCOMYCIN 500MG BOČICA
Cnp Pharma Gmbh Vankomicin Cnp VANCOMYCIN 500MG VIAL 
Cnp Pharma Gmbh Vankomicin Cnp VANCOMYCIN 500MG BOČICA
POWDER FOR ORAL SOLUTION, SOLUTION FOR INFUSION 
PRAŠAK ZA ORALNU OTOPINU, SOLUTION FOR INFUSION
Vancomycine Sandoz VANCOMYCIN HYDROCHLORIDE 
Sandoz Gmbh Vancomycin Sandoz VANCOMYCIN HYDROCHLORIDE
Vancomicina Pfizer VANCOMYCIN 1000MG VIAL 
Vancomicina Pfizer VANCOMYCIN 1000MG BOČICA
Cnp Pharma Gmbh Vancomycin Cnp VANCOMYCIN 1000MG VIAL 
Cnp Pharma Gmbh Vancomycin Cnp VANCOMYCIN 1000MG BOČICA
Cnp Pharma Gmbh Vancomycin Cnp VANCOMYCIN 500MG VIAL 
Cnp Pharma Gmbh Vancomycin Cnp VANCOMYCIN 500MG BOČICA
Vancomycine Pfizer VANCOMYCIN 500MG VIAL 
Vancomycine Pfizer VANCOMYCIN 500MG BOČICA
Vancomycin Teva VANCOMYCIN 1000 I.U. 
Vancomycin Teva VANCOMYCIN 1000 I.U. / MG
Vancomycin Pfizer VANCOMYCIN 1000MG VIAL 
Vancomycin Pfizer VANCOMYCIN 1000MG BOČICA
Cnp Pharma Gmbh Vancomicina CNP VANCOMYCIN 1000MG VIAL 
Cnp Pharma Gmbh Vancomicina CNP VANCOMYCIN 1000MG BOČICA
Vankomicin Pfizer VANCOMYCIN 500MG VIAL 
Vankomicin Pfizer VANCOMYCIN 500MG BOČICA
Vancomicina Pfizer VANCOMYCIN 500MG VIAL 
Vancomicina Pfizer VANCOMYCIN 500MG BOČICA
Vancomicina Labesfal VANCOMYCIN Hydrochloride 500MG vial 
Vancomycin Hospira VANCOMYCIN HYDROCHLORIDE 500MG BOČICA
Vancomycin Norma VANCOMYCIN 500MG VIAL 
Norma Hellas S.A. Vancomycin Norma VANCOMYCIN 500MG BOČICA
HYDROCHLORIDE 500MG VIAL 
HYDROCHLORIDE 500MG BOČICA
512.6 - 520.1MG VIAL 
512.571MG UNITS
Cnp Pharma Gmbh Vancomicina CNP VANCOMYCIN 500MG VIAL 
Cnp Pharma Gmbh Vancomicina CNP VANCOMYCIN 500MG BOČICA
Vancomycin Pfizer VANCOMYCIN 500MG VIAL 
Vancomycin Pfizer VANCOMYCIN 500MG BOČICA
VANCOMYCIN HYDROCHLORIDE 1MG VIAL 
VANCOMYCIN HYDROCHLORIDE 1MG BOČICA
Vancomicina Normon VANCOMYCIN 1G VIAL POWDER FOR SOLUTION FOR 
Vancomicina Normon VANCOMYCIN 1G BOČICA
Hospira Enterprise Bv Vancomycin Hospira VANCOMYCIN HYDROCHLORIDE 1G 
Vancomycin Hospira VANCOMYCIN HYDROCHLORIDE 1G BOČICA
VANCOMYCIN HYDROCHLORIDE 510MG VIAL 
VANCOMYCIN HYDROCHLORIDE 510MG BOČICA
MA (EU) number (Invented) name 
Broj (EU) odobrenja (Zaštićeno) ime Doza Farmaceutski oblik Put primjene
The dose in children depends on their age. 
Doza u djece ovisi o njihovoj dobi.
Adults and adolescents can use any form of the medicine. 
Odrasle osobe i adolescenti mogu koristiti bilo koji oblik lijeka.
The full EPAR for Neoclarityn can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Cjeloviti EPAR za lijek Neoclarityn nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The side effects seen in children are similar. 
Kod djece su uočene slične nuspojave.
The European Commission granted a marketing authorisation valid throughout the European Union for Neoclarityn on 15 January 2001. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Neoclarityn na snazi u Europskoj uniji od 15. siječnja 2001.
Neoclarityn has also been studied in 416 patients with urticaria. 
Neoclarityn je također ispitivan u 416 bolesnika s urtikarijom.
The recommended dose for adults and adolescents (12 years of age and over) is 5 mg once a day. 
Preporučena doza za odrasle osobe i adolescente (u dobi od 12 godina i stariji) iznosi 5 mg jednom na dan.
Additional studies were presented to show that the syrup, oral solution and orodispersible tablets are treated by the body in the same way as the tablets, and to show that they can be used safely in children. 
Predstavljena su dodatna ispitivanja kako bi se pokazalo da tijelo tretira sirup, oralnu otopinu i orodisperzibilne tablete na isti način kao tablete, te da bi se dokazalo da se mogu sigurno primjenjivati u djece.
In adults and adolescents, the most common side effects are fatigue (tiredness; 1.2%), dry mouth (0.8%) and headache (0.6%). 
U odraslih osoba i adolescenata, najčešće nuspojave bile su iscrpljenost (umor; 1,2 %), suha usta (0,8 %) i glavobolja (0,6 %).
This is a summary of the European public assessment report (EPAR) for Neoclarityn. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Neoclarityn.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Neoclarityn. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Neoclarityn.
In children less than two years of age, the most common side effects are diarrhoea (3.7%), fever (2.3%) and insomnia (difficulty sleeping; 2.3%). 
U djece mlađe od dvije godine, najčešće nuspojave su proljev (3,7 %), vrućica (2,3 %) i insomnija (poteškoće sa spavanjem; 2,3 %).
In all studies, the effectiveness of Neoclarityn was compared with that of placebo (a dummy treatment). 
U svim ispitivanjima, djelotvornost lijeka Neoclarityn uspoređena je s onom placeba (liječenja bez djelatne tvari).
For more information about treatment with Neoclarityn, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Neoclarityn pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
When the receptors are blocked, histamine cannot have its effect, and this leads to a decrease in the symptoms of allergy. 
Ako su receptori inhibirani, histamin ne može djelovati, te to rezultira ublažavanjem simptoma ili alergije.
In the two studies in urticaria, the decrease in symptom score after six weeks of treatment with Neoclarityn was 58 and 67%, compared with 40 and 33% in placebo-treated patients. 
U dva ispitivanja kod urtikarije, smanjenje u rezultatu simptoma nakon šest tjedana terapije lijekom Neoclarityn bilo je 58 do 67 %, u usporedbi sa 40 i 33 % u bolesnika liječenih placebom.
Neoclarityn has been studied in a total of eight studies involving about 4,800 adult and adolescent patients with allergic rhinitis (including four studies in seasonal allergic rhinitis, and two studies in patients who also had asthma). 
Neoclarityn je ispitivan u ukupno osam ispitivanja koja su obuhvatila 4 800 odraslih osoba i adolescenata s alergijskim rinitisom (uključujući ispitivanja u slučaju sezonskog alergijskog rinitisa i dva ispitivanja u bolesnika koji su također imali astmu).
It is available as a 5 mg tablet, 2.5 mg and 5 mg orodispersible tablets (tablets that dissolve in the mouth), a 0.5 mg/ml syrup and a 0.5 mg/ml oral solution. 
Dostupan je kao tablete od 5 mg, orodisperzibilne tablete (tablete koje se otapaju u ustima) od 2,5 mg i 5 mg, sirup od 0,5 mg/ml i oralna otopina od 0,5 mg/ml.
Neoclarityn is a medicine containing the active substance desloratadine. 
Neoclarityn je lijek koji sadrži djelatnu tvar desloratadin.
The active substance in Neoclarityn, desloratadine, is an antihistamine. 
Djelatna tvar lijeka Neoclarityn, desloratadin, je antihistamin.
The effectiveness was measured by looking at the change in the symptoms (itching, number and size of hives, interference with sleep and daytime function) before and after six weeks of treatment. 
Djelotvornost je mjerena promatranjem promjena simptoma (svrbež, broj i veličina osipa, poremećaji spavanja i dnevnih funkcija) prije i nakon šest tjedana terapije.
Other information about Neoclarityn 
Ostale informacije o lijeku Neoclarityn
In allergic rhinitis, looking at the results of all studies taken together, two weeks of treatment with 5 mg Neoclarityn led to an average decrease in symptom score of 25 to 32%, compared with a decrease of 12 to 26% in the patients receiving placebo. 
U slučaju alergijskog rinitisa, promatrajući rezultate svih ispitivanja zajedno, nakon dva tjedna terapije lijekom Neoclarityn od 5 mg došlo je do prosječnog smanjenja simptoma od 25 do 32 %, u usporedbi sa smanjenjem od 12 do 26% u bolesnika koji su primali placebo.
EPAR summary for the public desloratadine 
EPAR, sažetak za javnost
Why has Neoclarityn been approved? 
Zašto je Neoclarityn odobren?
Neoclarityn is used to relieve the symptoms of allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) or urticaria (a skin condition caused by an allergy, with symptoms including itching and hives). 
Neoclarityn se koristi za ublažavanje simptoma alergijskog rinitisa (upale nosnih putova uzrokovane alergijom, primjerice alergijom na sijeno ili alergijom na prašinske grinje) ili urtikarije (stanje kože uzrokovano alergijom, sa simptomima koji uključuju svrbež i osip).
It works by blocking the receptors to which histamine, a substance in the body that causes allergic symptoms, normally attaches itself. 
Djeluje inhibirajući receptore na koje se normalno vezuje histamin, tvar u tijelu koja uzrokuje alergijske simptome.
Neoclarityn must not be used in people who are hypersensitive (allergic) to desloratadine, loratadine or any of the other ingredients. 
Neoclarityn se ne smije primjenjivati u osoba koje su preosjetljive (alergične) na desloratadin ili na bilo koju drugu pomoćnu tvar.
The CHMP decided that Neoclarityn's benefits are greater than its risks for the relief of symptoms associated with allergic rhinitis or urticaria and recommended that it be given marketing authorisation. 
CHMP je odlučio da koristi lijeka Neoclarityn premašuju s njim povezane rizike za ublažavanje simptoma povezanih s alergijskim rinitisom ili urtikarijom i preporučio je izdavanje odobrenja za stavljanje lijeka u promet.
What is Neoclarityn? 
Što je Neoclarityn?
What is the risk associated with Neoclarityn? 
Koji su rizici povezani s lijekom Neoclarityn?
The effectiveness of Neoclarityn was measured by looking at the change in the symptoms (nasal discharge, itching, sneezing and congestion) before and after two or four weeks of treatment. 
Djelotvornost lijeka Neoclarityn mjerena je promatranjem promjena simptoma (iscjedak iz nosa, svrbež, kihanje i zatvor) prije i nakon dva ili četiri tjedna terapije.
For children from one to five years of age, the dose is 1.25 mg once a day, taken as 2.5 ml syrup or oral solution. 
U djece u dobi od jedne do pet godina, doza od 1,25 mg jednom na dan uzima se kao sirup ili oralna otopina od 2,5 ml.
For children from six to 11 years of age, the dose is 2.5 mg once a day, taken either as 5 ml of the syrup or oral solution, or as one 2.5 mg orodispersible tablet. 
U djece od šest do 11 godina, doza se uzima jednom na dan, i to kao 5 ml sirupa ili oralne otopine ili kao jedna orodisperzibilna tableta od 2,5 mg.
What is Neoclarityn used for? 
Za što se Neoclarityn koristi?
For the full list of all side effects reported with Neoclarityn, see the package leaflet. 
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Neoclarityn potražite u uputi o lijeku.
What benefit has Neoclarityn shown during the studies? 
Koje su koristi lijeka Neoclarityn utvrđene u ispitivanjima?
How is Neoclarityn used? 
Kako se Neoclarityn koristi?
How has Neoclarityn been studied? 
Kako je Neoclarityn ispitivan?
How does Neoclarityn work? 
Kako djeluje Neoclarityn?
Its terminal half-life is 0.6-2 hours. 
Njegov terminalni poluvijek je 0,6-2 sata.
Some of these events have been reported more than 1-year after initiation of treatment. 
Neki od tih događaja zabilježeni su nakon više od godine dana od početka liječenja.
- If you see or hear things which are not there (hallucinations). 
Ako vidite ili čujete stvari koje nisu stvarne (halucinacije).
These cases were considered serious in all reports. 
Ti su slučajevi u svim prijavama smatrani ozbiljnima.
Blisters: 3 years Bottles: 3 years 
Bočice: 3 godine
Contact you doctor right away if you notice any of the following symptoms. 
Odmah se obratite svom liječniku ako primijetite bilo koji od sljedećih simptoma.
- If you have severe liver problems. 
- ako imate teške probleme s jetrom.
Hallucinations*, Abnormal dreams 
Halucinacije*, Abnormalni snovi
Only single cases of reported cases had not recovered at the time they were reported. 
Samo u pojednim od svih prijavljenih slučajeva nije došlo do oporavka u vrijeme prijave.
Tell your doctor or pharmacist if you are smoking or intend to stop smoking. 
Obavijestite svog liječnika ili ljekarnika ako pušite ili namjeravate prestati pušiti.
Less than 1% of rasagiline is excreted as unchanged product in urine. 
Manje od 1 % razagilina se izlučuje nepromijenjeno u urinu.
Take the next dose normally, when it is time to take it. 
Uzmite sljedeću dozu u uobičajeno vrijeme.
Parkinson's disease is associated with symptoms of hallucinations and confusion. 
Parkinsonova bolest se povezuje sa simptomima halucinacija i konfuzije.
Teva Operations Poland Sp.z o.o. 
Teva Operations Poland Sp.z o.o. ul.
Your doctor may need to adjust or stop your dose (see section 4). 
Vaš liječnik će možda morati prilagoditi dozu ili prekinuti liječenje (vidjeti dio 4).
Smoking could decrease the amount of Rasagiline ratiopharm in the blood. 
Pušenje može smanjiti količinu Razagilin ratiopharma u krvi.
Talk to your doctor before taking Rasagiline ratiopharm - If you have any liver problems - You should speak with your doctor about any suspicious skin changes. 
Obratite se svom liječniku prije nego uzmete Razagilin ratiopharm - ako imate bilo kakve probleme s jetrom - morali biste razgovarati sa svojim liječnikom o bilo kakvim sumnjivim promjenama na koži.
4.5 Interaction with other medicinal products and other forms of interaction MAO Inhibitors 
4.5 Interakcije s drugim lijekovima i drugi oblici interakcija MAO inhibitori
No change in dose is required for elderly patients (see section 5.2). 
Nije potrebna promjena doze kod starijih bolesnika (vidjeti dio 5.2).
It can be used together with or without Levodopa (another medicine that is used to treat Parkinson's disease). 
Može se primjeniti zajedno s levodopom ili bez levodope (drugi lijek koji se primjenjuje za liječenje Parkinsonove bolesti).
Pharmacotherapeutic group: Anti-Parkinson-Drugs, monoamine oxidase -B inhibitors, ATC code: N04BD02 
Farmakoterapijska skupina: Antiparkinsonici, inhibitori monoaminooksidaze B, ATK oznaka: N04BD02
For further information please refer to section driving and using machines. 
Za više informacija proučite dio o upravljanju vozilima i radu sa strojevima.
Adverse reactions are listed below in Tables 1 and 2 by system organ class and frequency using the following conventions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Nuspojave su navedene u tablicama 1 i 2 prema klasifikaciji organskih sustava i učestalosti prema sljedećem pravilu: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1 000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1 000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
These symptoms may resemble those observed with nonselective MAO inhibitors. 
Ovi simptomi mogu nalikovati na one opažene kod neselektivnih MAO inhibitora.
Decreasing the dose of levodopa may ameliorate this adverse reaction. 
Sniženje doze levodope može ublažiti ovu nuspojavu.
This might be enhanced if you take other medicines to treat the symptoms of your Parkinson's disease, or if you take medicines which can make you feel drowsy, or if you drink alcohol while taking Rasagiline ratiopharm. 
To se može pojačati ako uzimate druge lijekove za liječenje simptoma Parkinsonove bolesti ili ako uzimate lijekove koji Vas mogu omamiti ili pijete alkohol dok uzimate Razagilin ratiopharm.
- Elevated blood pressure - Excessive drowsiness - Sudden onset of sleep 
- povišeni krvni tlak - prekomjerna omamljenost - iznenadni nastup sna
White, high-density polyethylene bottle with or without a child-resistant cap containing 30 tablets. 
Bijele bočice od polietilena visoke gustoće sa ili bez sigurnosnog zatvarača za djecu koje sadržavaju 30 tableta.
12 January 2015 
Datum prvog odobrenja: 12. siječanj 2015.
Skin carcinoma 
Karcinom kože
If you take more Rasagiline ratiopharm than you should If you think that you may have taken too many Rasagiline ratiopharm tablets, contact your doctor or pharmacist immediately. 
Ako uzmete više Razagilin ratiopharma nego što ste trebali Ako mislite da ste možda uzeli previše Razagilin ratiopharm tableta, odmah se obratite svom liječniku ili ljekarniku.
Tyramine/rasagiline interaction 
Tiramin/razagilin interakcija
Non-clinical data reveal no special hazard for humans based on the standard studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, reproduction and development. 
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenog potencijala, reproduktivne i razvojne toksičnosti.
These results indicate that rasagiline's therapeutic concentrations are unlikely to cause any clinically significant interference with substrates of these enzymes (see section 5.3). 
Ovi rezultati indiciraju da nije vjerojatno da terapijske koncentracije razagilina prouzročuju bilo kakvu klinički značajnu interferenciju sa supstratima ovih enzima (vidjeti dio 5.3).
Malignant melanoma 
Maligni melanom
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). 
Ispitivanja na životinjama ne ukazuju na izravne ili neizravne štetne učinke na reprodukciju (vidjeti dio 5.3).
Age has little influence on rasagiline pharmacokinetics in the elderly (> 65 years) (see section 4.2) 
Dob slabo utječe na farmakokinetiku razagilina u starijih osoba (> 65 godina) (vidjeti dio 4.2).
As a precautionary measure, it is preferable to avoid the use of rasagiline during pregnancy. 
Kao mjera opreza, preporučuje se izbjegavati primjenu razagilina tijekom trudnoće.
Depression, Hallucinations* 
Depresija Halucinacije*
If increased somnolence or new episodes of falling asleep during activities of daily living (e.g. watching television, passenger in a car, etc.) are experienced at any time during treatment, the patients should not drive or participate in potentially dangerous activities. 
U slučaju povećane somnolencije ili novih epizoda nastupa sna tijekom dnevnih aktivnosti (primjerice, gledanja televizije, vožnje u automobilu kao putnik itd.) bilo kada tijekom liječenja, bolesnik ne smije voziti niti sudjelovati u potencijalno opasnim aktivnostima.
Additional cases of malignant melanoma were reported during post-marketing period. 
Dodatni slučajevi malignog melanoma prijavljeni su tijekom razdoblja nakon stavljanja lijeka u promet.
7 tablets 10 tablets 28 tablets 30 tablets 100 tablets 112 tablets 10 x 1 tablets 30 x 1 tablets 100 x 1 tablets 
7 tableta 10 tableta 28 tableta 30 tableta 100 tableta 112 tableta 10 x 1 tableta 30 x 1 tableta 100 x 1 tableta
Prilaz baruna Filipovica 25 10000 Zagreb Croatia 
Pliva Hrvatska d.o.o Prilaz baruna Filipovića 25 10000 Zagreb Hrvatska
The absolute bioavailability of a single rasagiline dose is about 36%. 
Apsolutna bioraspoloživost pojedinačne doze razagilina je oko 36 %.
Take the Rasagiline ratiopharm carton/ blister or bottle with you to show the doctor or pharmacist. 
Ponesite sa sobom kutiju/blister ili bočicu Razagilin ratiopharma da pokažete svom liječniku ili ljekarniku.
Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines (see section 4.7). 
Bolesnici koji su osjetili somnolenciju i/ili epizodu iznenadnog nastupa sna moraju se suzdržati od upravljanja vozilima i rada sa strojevima (vidjeti dio 4.7).
Rasagiline selectively inhibits MAO-B and is not associated with increased tyramine sensitivity at the indicated dose (1 mg/day). 
Razagilin selektivno inhibira MAO-B te nije povezan s povećanom osjetljivošću na tiramin pri naznačenoj dozi (1 mg/dan).
Patients should not drive, operate machinery, or work at heights during treatment if they have previously experienced somnolence and/or have fallen asleep without warning prior to use of rasagiline. 
Bolesnici ne smiju voziti, upravljati strojevima ili raditi na visinama tijekom liječenja ako su prethodno osjećali somnolenciju i/ili zaspali bez upozorenja prije primjene razagilina.
The metabolism of rasagiline proceeds through two main pathways: N-dealkylation and/or hydroxylation to yield: 1aminoindan, 3-hydroxy-N-propargyl-1 aminoindan and 3-hydroxy-1-aminoindan. 
Metabolizam razagilina se odvija kroz dva glavna puta: N-dealkilacijom i/ili hidroksilacijom te nastaju: 1-aminoindan, 3-hidroksi-N-propargil-1 aminoindan i 3-hidroksi-1 aminoindan.
These adverse reactions were not associated with an elevated rate of drug discontinuation. 
Te nuspojave nisu bile povezane s povećanom stopom prestanka primjene lijeka.
*See section description of selected adverse reactions 
*Vidjeti dio s opisom odabranih nuspojava
Rasagiline ratiopharm helps to increase and sustain levels of dopamine in the brain. 
Razagilin ratiopharm pomaže u povećavanju i održavanju razina dopamina u mozgu.
Abdominal pain, Constipation, Nausea and vomiting, Dry mouth 
Bol u abdomenu, Konstipacija, Mučnina i povraćanje, Suha usta
SNRI/SSRI/tri- and tetracyclic antidepressants 
SNRI/SSRI/triciklički i tetraciklički antidepresivi
Although many of these patients reported somnolence while on rasagiline with other dopaminergic medicinal products, some perceived that they had no warning signs, such as excessive drowsiness, and believed that they were alert immediately prior to the event. 
Iako je većina ovih bolesnika prijavila somnolenciju dok je primala razagilin u kombinaciji s drugim dopaminergičkim lijekovima, neki nisu osjetili znakove upozorenja poput prekomjerne omamljenosti i vjerovali su da su neposredno prije događaja bili prisebni.
You should avoid taking Rasagiline ratiopharm if you are pregnant, as the effects of Rasagiline ratiopharm on pregnancy and the unborn child are not known. 
Trebali biste izbjegavati uzimanje Razagilin ratiopharma ako ste trudni, jer nije poznato kako Razagilin ratiopharm utječe na trudnoću i nerođeno dijete.
Adverse reactions were mild or moderate and not related to rasagiline treatment. 
Nuspojave su bile blage ili umjerene i nisu bile povezane s liječenjem razagilinom.